Phase I/II study of AZD6750, a CD8-guided interleukin-2 agent, alone and in combination with other anti-cancer agents in participants with advanced or metastatic solid tumors.

AZD6750 - AstraZeneca

rilvegostomig (AZD2936) - AstraZeneca

https://www.asco.org/abstracts-presentations/266794

Drew Rasco; Ko Sugibayashi; Deborah Andrew; Simon Rodney; Nadia Luheshi; Emily Hsiue; Shahneen Sandhu; Shigehiro Koganemaru; Takafumi Koyama; Manish Sharma; Stephane Champiat; Diwakar Davar; Tanner Johanns; Alexander Spira; Nairouz Elgeioushi

Apr 21, 2026